Taken together, there is a possibility that the treatment with PCO causes elevation of HDL-C and enhancement of HDL functionality to induce the reduction of oxidized species (4-HNE and iNOS), inflammatory cytokines (IL-1β, IL-6, and TNF-α), and amyloid plaque size. The gene discussed is IL1B; the disease is amyloidosis.